BofA Calls Bicara Therapeutics a Buy – Sees Ficerafusp Alfa as Transformative

BofA starts coverage on Bicara Therapeutics with a Buy rating and $35 price target. Ficerafusp alfa shows strong potential in head and neck cancer with clear differentiation over standard care.